Latest news
NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US
HBC accelerates in Human Health and Pet Nutrition through a strategic partnership with Symrise to build out Berkåk, tripling the manufacturing capacity of the group
Groundbreaking study reveals Hofseth BioCare’s full spectrum omegas OmeGo® supports COVID-19 recovery
Hofseth BioCare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.
Hofseth BioCare agrees China distribution partnership with Shanghai-based Lithy
Study unveils the potential of HBC’s ProGo® bioactive peptides to regulate glucose and improve metabolic health
Hofseth BioCare ASA successfully completed seed round capital raise in HBC Immunology LLC at $20M valuation for the development of a new prostate cancer co-therapy
New bioavailability study underlines OmeGo®’s ability to unlock the full potential of fresh, whole fish compared to processed 18/12 omega-3 oils
New study uncovers the ability of OmeGo® to temper type 1 inflammation
2022: A year of great achievements for HBC
Hofseth BioCare’s OmeGo® could hold the key to restoring respiratory health and rebalancing the immune system, reveals new study
HBC The Deep Dive: ProGo® under the microscope
Trailblazing Stanford University study highlights promise of ProGo® bioactive peptides in effective gut health support
Food for thought: Spotlight on sustainability at Fi Asia
HBC The Deep Dive: OmeGo® under the microscope
Hofseth BioCare wins 2022 Ringier Technology Innovation Award
ProGo® proven to go beyond nutrition as it earns several new FDA structure function claims
ProGo® bioactive peptides is acknowledged as ‘New Dietary Ingredient’ (NDI) by the FDA
Unique quality approval from US health authorities
Aquaculture fund new significant shareholder in HBC
Latest stock exchange notices
All notices